Verrica Pharmaceuticals (VRCA) Other Non-Current Liabilities (2020 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Other Non-Current Liabilities of $5.8 million for Q1 2026, up 142.86% year-over-year from $2.4 million in Q1 2025, and up 14.77% quarter-over-quarter from $5.1 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $5.8 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 142.86% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 142.86% YoY), while the FY2025 annual figure was $5.1 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $5.8 million, up from $5.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $5.8 million in Q1 2026, with the low at $5000.0 in Q3 2023.
- The 3-year median for Other Non-Current Liabilities is $2.4 million (2025), against an average of $2.8 million.
- Peak annual rise in Other Non-Current Liabilities reached 142.86% in 2026, while the deepest fall reached 142.86% in 2026.
- Verrica Pharmaceuticals' Other Non-Current Liabilities stood at $5000.0 in 2023, then surged by 101220.0% to $5.1 million in 2025, then gained by 14.77% to $5.8 million in 2026.
- Business Quant data shows VRCA's Other Non-Current Liabilities at $5.8 million in Q1 2026, $5.1 million in Q4 2025, and $4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.41 Mn |
| Mar 31, 2026 | 5.81 Mn |
| Dec 31, 2025 | 5.07 Mn |
| Sep 30, 2025 | 4.69 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 2.39 Mn |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 10,000.00 |
| Jun 30, 2020 | 75,000.00 |
| Mar 31, 2020 | 75,000.00 |